Capsular contracture is among the most common causes for breast surgery revision. Clinically significant capsular contracture is characterized by excessive scar formation, fibrosis around the implant, along with distortion and displacement of the breast implant. Multiple factors likely contribute to contracture, including the presence of biofilms on surgical implants and devices. Biofilms represent a complex problem in wound healing as their makeup can consist of one or numerous species of microorganisms that secrete cross-linking extracellular polymeric substances. Safe Acid Technology (SAT) disinfectant has been developed to destroy microorganisms and the biofilms they create while maintaining an impeccable safety profile for the user.
SAT anti-biofilm testing was administered by the Montana State University Center for BioFilm Engineering using a single species (Pseudomonas aeruginosa) biofilm grown in the CDC reactor according to ASTM E2871-12 on polycarbonate coupons. After establishing biofilms, the polycarbonate coupons were exposed to SAT formulations for multiple exposure times in varied concentrations.
Log reductions of biofilm ranged from 3.61 for treatment C50 at the low end and 4.82 for treatment C25 at the high end, compared to biofilm accumulated on control coupons of Log 8.62.
With biofilm being the leading suspect in the formation of capsular contracture in breast augmentation cases, employing strategies to minimize microbial infiltration of the implantation cavity is critical. SAT has demonstrated strong microbicidal and anti-biofilm action while maintaining a superior safety profile. SAT has achieved Category IV (harmless) designation in the FDA’s Toxic 6-Pack assessment. This unique set of dual properties, efficacy vs microbes and nontoxicity, make SAT a promising candidate to use prophylactically in breast augmentation cases.